Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

N/A

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 1(4)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07228325Phase 1Enrolling By Invitation

Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis

Role: lead

NCT07045701Phase 2Enrolling By Invitation

FMXIN002 in Patients at Risk of Anaphylaxis

Role: lead

NCT06205134Phase 1Completed

Comparative Bioavailability of Intranasal Epinephrine

Role: lead

NCT04696822Phase 1Completed

Bioavailability of Nasal Epinephrine

Role: lead

NCT04713709Phase 1Completed

A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder

Role: lead

NCT05252468Not ApplicableCompleted

COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).

Role: lead

All 6 trials loaded